Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines

M. Nabil Benchekroun, Erasmus Schneider, Ahmad Safa, Alan J. Townsend, Birandra K. Sinha

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

We recently reported that multidrug-resistant, P-170 glycoprotein- positive, Adriamycin-selected, human breast tumor (MCF7/ADR(R)) cells were resistant to the benzoquinonoid ansamycin antibiotics geldanamycin (GL) and herbimycin A (HA) and that significantly fewer hydroxyl radicals were formed in resistant cells. We have carried out additional studies to define the mechanisms of cytotoxicity of and resistance to GL and HA, by directly examining the interactions of these drugs with P-170 glycoprotein using photoaffinity labeling. We found that both GL and HA inhibited binding of azidopine to P-170 glycoprotein in a dose-dependent manner. We have developed a 10-fold GL-resistant cell line (MCF7/GL(R)) by continuous drug exposure. Our studies indicated no significant differences in free radical formation between wild-type MCF7 cells and MCF7/GL(R) cells. Uptake and efflux studies indicated a small decrease in the GL accumulation but no difference in the efflux of GL in these cells. Verapamil had no effect on cellular accumulation of GL in wild-type MCF7 cells or MCF7/GL(R) cells. Verapamil significantly increased the accumulation of GL in MCF7/ADR(R) cells and enhanced GL cytotoxicity 12-fold, suggesting that GL interacted with the P-170 glycoprotein. Using reverse transcription-polymerase chain reaction, we found no expression of the mdr1 gene; however, expression of the multidrug resistance-associated protein was about 2-fold higher in MCF7/GL(R) cells. Taken together, these studies indicate that the mechanisms of GL resistance are multifactorial. Although decreased free radical formation may not play a significant role in low levels of GL resistance, e.g., in MCF7/GL(R) cells, both overexpression of mdr1 and decreased free radical formation contribute to GL resistance in highly resistant cells such as MCF7/ADR(R) cells.

Original languageEnglish (US)
Pages (from-to)677-684
Number of pages8
JournalMolecular Pharmacology
Volume46
Issue number4
StatePublished - Oct 1994
Externally publishedYes

Fingerprint

Rifabutin
Breast Neoplasms
Anti-Bacterial Agents
Cell Line
P-Glycoprotein
Free Radicals
geldanamycin
MCF-7 Cells
Verapamil
Multidrug Resistance-Associated Proteins

ASJC Scopus subject areas

  • Pharmacology

Cite this

Benchekroun, M. N., Schneider, E., Safa, A., Townsend, A. J., & Sinha, B. K. (1994). Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines. Molecular Pharmacology, 46(4), 677-684.

Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines. / Benchekroun, M. Nabil; Schneider, Erasmus; Safa, Ahmad; Townsend, Alan J.; Sinha, Birandra K.

In: Molecular Pharmacology, Vol. 46, No. 4, 10.1994, p. 677-684.

Research output: Contribution to journalArticle

Benchekroun, MN, Schneider, E, Safa, A, Townsend, AJ & Sinha, BK 1994, 'Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines', Molecular Pharmacology, vol. 46, no. 4, pp. 677-684.
Benchekroun MN, Schneider E, Safa A, Townsend AJ, Sinha BK. Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines. Molecular Pharmacology. 1994 Oct;46(4):677-684.
Benchekroun, M. Nabil ; Schneider, Erasmus ; Safa, Ahmad ; Townsend, Alan J. ; Sinha, Birandra K. / Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines. In: Molecular Pharmacology. 1994 ; Vol. 46, No. 4. pp. 677-684.
@article{56bf0a3d191546a2ae8089eeaec27509,
title = "Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines",
abstract = "We recently reported that multidrug-resistant, P-170 glycoprotein- positive, Adriamycin-selected, human breast tumor (MCF7/ADR(R)) cells were resistant to the benzoquinonoid ansamycin antibiotics geldanamycin (GL) and herbimycin A (HA) and that significantly fewer hydroxyl radicals were formed in resistant cells. We have carried out additional studies to define the mechanisms of cytotoxicity of and resistance to GL and HA, by directly examining the interactions of these drugs with P-170 glycoprotein using photoaffinity labeling. We found that both GL and HA inhibited binding of azidopine to P-170 glycoprotein in a dose-dependent manner. We have developed a 10-fold GL-resistant cell line (MCF7/GL(R)) by continuous drug exposure. Our studies indicated no significant differences in free radical formation between wild-type MCF7 cells and MCF7/GL(R) cells. Uptake and efflux studies indicated a small decrease in the GL accumulation but no difference in the efflux of GL in these cells. Verapamil had no effect on cellular accumulation of GL in wild-type MCF7 cells or MCF7/GL(R) cells. Verapamil significantly increased the accumulation of GL in MCF7/ADR(R) cells and enhanced GL cytotoxicity 12-fold, suggesting that GL interacted with the P-170 glycoprotein. Using reverse transcription-polymerase chain reaction, we found no expression of the mdr1 gene; however, expression of the multidrug resistance-associated protein was about 2-fold higher in MCF7/GL(R) cells. Taken together, these studies indicate that the mechanisms of GL resistance are multifactorial. Although decreased free radical formation may not play a significant role in low levels of GL resistance, e.g., in MCF7/GL(R) cells, both overexpression of mdr1 and decreased free radical formation contribute to GL resistance in highly resistant cells such as MCF7/ADR(R) cells.",
author = "Benchekroun, {M. Nabil} and Erasmus Schneider and Ahmad Safa and Townsend, {Alan J.} and Sinha, {Birandra K.}",
year = "1994",
month = "10",
language = "English (US)",
volume = "46",
pages = "677--684",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

TY - JOUR

T1 - Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines

AU - Benchekroun, M. Nabil

AU - Schneider, Erasmus

AU - Safa, Ahmad

AU - Townsend, Alan J.

AU - Sinha, Birandra K.

PY - 1994/10

Y1 - 1994/10

N2 - We recently reported that multidrug-resistant, P-170 glycoprotein- positive, Adriamycin-selected, human breast tumor (MCF7/ADR(R)) cells were resistant to the benzoquinonoid ansamycin antibiotics geldanamycin (GL) and herbimycin A (HA) and that significantly fewer hydroxyl radicals were formed in resistant cells. We have carried out additional studies to define the mechanisms of cytotoxicity of and resistance to GL and HA, by directly examining the interactions of these drugs with P-170 glycoprotein using photoaffinity labeling. We found that both GL and HA inhibited binding of azidopine to P-170 glycoprotein in a dose-dependent manner. We have developed a 10-fold GL-resistant cell line (MCF7/GL(R)) by continuous drug exposure. Our studies indicated no significant differences in free radical formation between wild-type MCF7 cells and MCF7/GL(R) cells. Uptake and efflux studies indicated a small decrease in the GL accumulation but no difference in the efflux of GL in these cells. Verapamil had no effect on cellular accumulation of GL in wild-type MCF7 cells or MCF7/GL(R) cells. Verapamil significantly increased the accumulation of GL in MCF7/ADR(R) cells and enhanced GL cytotoxicity 12-fold, suggesting that GL interacted with the P-170 glycoprotein. Using reverse transcription-polymerase chain reaction, we found no expression of the mdr1 gene; however, expression of the multidrug resistance-associated protein was about 2-fold higher in MCF7/GL(R) cells. Taken together, these studies indicate that the mechanisms of GL resistance are multifactorial. Although decreased free radical formation may not play a significant role in low levels of GL resistance, e.g., in MCF7/GL(R) cells, both overexpression of mdr1 and decreased free radical formation contribute to GL resistance in highly resistant cells such as MCF7/ADR(R) cells.

AB - We recently reported that multidrug-resistant, P-170 glycoprotein- positive, Adriamycin-selected, human breast tumor (MCF7/ADR(R)) cells were resistant to the benzoquinonoid ansamycin antibiotics geldanamycin (GL) and herbimycin A (HA) and that significantly fewer hydroxyl radicals were formed in resistant cells. We have carried out additional studies to define the mechanisms of cytotoxicity of and resistance to GL and HA, by directly examining the interactions of these drugs with P-170 glycoprotein using photoaffinity labeling. We found that both GL and HA inhibited binding of azidopine to P-170 glycoprotein in a dose-dependent manner. We have developed a 10-fold GL-resistant cell line (MCF7/GL(R)) by continuous drug exposure. Our studies indicated no significant differences in free radical formation between wild-type MCF7 cells and MCF7/GL(R) cells. Uptake and efflux studies indicated a small decrease in the GL accumulation but no difference in the efflux of GL in these cells. Verapamil had no effect on cellular accumulation of GL in wild-type MCF7 cells or MCF7/GL(R) cells. Verapamil significantly increased the accumulation of GL in MCF7/ADR(R) cells and enhanced GL cytotoxicity 12-fold, suggesting that GL interacted with the P-170 glycoprotein. Using reverse transcription-polymerase chain reaction, we found no expression of the mdr1 gene; however, expression of the multidrug resistance-associated protein was about 2-fold higher in MCF7/GL(R) cells. Taken together, these studies indicate that the mechanisms of GL resistance are multifactorial. Although decreased free radical formation may not play a significant role in low levels of GL resistance, e.g., in MCF7/GL(R) cells, both overexpression of mdr1 and decreased free radical formation contribute to GL resistance in highly resistant cells such as MCF7/ADR(R) cells.

UR - http://www.scopus.com/inward/record.url?scp=0028104545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028104545&partnerID=8YFLogxK

M3 - Article

C2 - 7969046

AN - SCOPUS:0028104545

VL - 46

SP - 677

EP - 684

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 4

ER -